0000950170-24-070694.txt : 20240607
0000950170-24-070694.hdr.sgml : 20240607
20240607162836
ACCESSION NUMBER: 0000950170-24-070694
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240605
FILED AS OF DATE: 20240607
DATE AS OF CHANGE: 20240607
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sulzberger Gabrielle
CENTRAL INDEX KEY: 0001262388
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39311
FILM NUMBER: 241029969
MAIL ADDRESS:
STREET 1: 450 LEXINGTON AVENUE, FLOOR 13
CITY: NEW YORK
STATE: NY
ZIP: 10017
FORMER NAME:
FORMER CONFORMED NAME: Greene-Sulzberger Gabrielle
DATE OF NAME CHANGE: 20141030
FORMER NAME:
FORMER CONFORMED NAME: GREENE GABRIELLE E
DATE OF NAME CHANGE: 20030904
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc.
CENTRAL INDEX KEY: 0001805387
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 JACOBS STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 844-304-2048
MAIL ADDRESS:
STREET 1: 222 JACOBS STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
FORMER COMPANY:
FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II
DATE OF NAME CHANGE: 20200303
4
1
ownership.xml
4
X0508
4
2024-06-05
0001805387
Cerevel Therapeutics Holdings, Inc.
CERE
0001262388
Sulzberger Gabrielle
C/O CEREVEL THERAPEUTICS HOLDINGS, INC.
222 JACOBS STREET, SUITE 200
CAMBRIDGE
MA
02141
true
false
false
false
false
Common Stock
2024-06-05
4
A
false
10461
A
58876
D
The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company.
/s/ Mark Bodenrader, as Attorney-in-Fact
2024-06-07